Plain-English translation of NCT06928272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large international study testing whether two existing medications— and —can help reduce long COVID symptoms. Both drugs have been used safely for other diseases, and researchers believe they might also help with the lingering effects of COVID-19. You would receive one of these medications or a placebo (a pill with no active ingredient) to see if it improves your symptoms.
Long COVID affects millions of people worldwide, but we still don't have proven treatments. This study uses an approach called 'drug repurposing'—testing whether medications already approved and used safely for other conditions might also work for long COVID. By doing this, researchers can move faster than developing completely new drugs.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either one of the two study medications or a matching placebo, and neither you nor the researchers would know which you're getting (this is called 'blinded'). The study involves enrolling about 348 people globally across multiple countries. You would likely need to attend clinic visits for assessments, answer questions about your symptoms, and possibly have blood tests, though the exact schedule isn't detailed here. After the first phase ends, researchers will analyze the results and may test additional drug combinations in a second phase.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Brazil
Canada
Italy